Description: Expect to cover key points from the Living to 100 conference around living and social environments for the elderly. Following the review will be a discussion about implications related to LTCI plans and policies around living environments. It will conclude with a peak behind the curtain for pricing for CCRCs.

Description: Join us as we summarize the impacts of recent studies from 2022, which update individual disability incidence rates and analyze the impact of the COVID-19 pandemic. Also, we will look at expectations for the disability insurance market. By attending this session, attendees will: - Identify the impact of recent experience adjustments to incidence rates. - Understand the impact of the COVID-19 pandemic on disability coverage. - Discover emerging issues likely to influence disability coverage in upcoming years.

Description: The session is based on an article of the same name featured in the January, 2023 issue of Health Watch. It gives a step-by-step method of how to apply the average paid PMPM method to calculate IBNR with zero run-out, as opposed to current methods, which generally require a three-month run-out period. Methods for obtaining confidence intervals for the IBNR estimates will also be discussed.

Description: Explore the value and cost of prescription drugs, how they should be defined and measured and the effects various stakeholders in the pharmacy ecosystem can have on these factors in the latest webcast. You'll investigate the impact of coverage, formulary and rebate negotiations and related benefit design. Find out how actuaries can answer questions related to the prescription drug industry, in addition to improving the access, quality and affordability of prescription drugs in the United States. Join us for this webcast and come learn about value-based contract design, negotiations, implementation and administration for prescription drugs.

Description: Hear a summary of the discussion from the Health Section's Pharmacy Partnership Forum in March 2023 entitled 'Reimagining Pharmacy Financing' where a multi-disciplinary group of clinicians, health economists, academics, and actuaries met and discussed the following questions: How do we define the value of prescription drugs? How do we measure the value of prescription drugs? How do we scalably and meaningfully apply the answers?

Description: The Inflation Reduction Act represents the largest change to the Medicare Part D program since its inception in 2006. With a complete redesign of the Part D program coming in 2025 (the next bid cycle), there are health plan, operational and analytical challenges that lie ahead. In this session, you will: Hear highlights on some of the key changes occurring in 2025 Learn about key considerations for health plans and other stakeholders in the Medicare and commercial markets Discover potential winning strategies and potential analyses that could inform those strategies

Description: Understand the role of food based interventions in health care. Learn the difference between produce prescription and medically tailored meals. Review new policies that will affect Medicare and Medicaid populations. Evaluate the possibility of health cost savings due to these interventions.

Description: Session 4B: Impact of GLP-1 Drugs on Health Care Cost Trend and Clinical Outcomes

Description: The rising interest rate environment has presented more attractive alternatives for VA risk management, but the benefits of different strategies can vary significantly by block of business. This session will highlight key drivers for risk management decisions for variable, fixed index, and registered index-linked annuities. With the viewpoints from different direct writers, reinsurers and preliminary findings of the 2024 Milliman Derivatives Study, the session will then show how product mix, tenure, and regulatory regime influence strategic decision-making. At the end of the session, the audience will help make strategic decisions on sample blocks of business and see how their choices play out in different hypothetical scenarios.

Description: The recent wave of innovation in GenAI has unlocked an entirely new category of AI applications. Whereas AI has traditionally focused on automation and predictions, LLM’s and Generative AI give us the opportunity to create AI applications that act as copilots. This emphasis on contelligence and empowering knowledge workers has already begun to change the way work is done. High expertise knowledge workers such as actuaries will be able to use this wave of AI Apps to make better decisions and dedicate more of their attention to the parts of the role that require domain expertise and judgement. Join Charles Morris, Microsoft’s Chief Data Scientist for Financial Services, as he talks about the latest advancements in this space and the opportunities it creates for expert knowledge workers. Charles Morris is the Chief Data Scientist for Financial Services at Microsoft. Charles has deep expertise in the financial services domain and works with many of the world’s leading asset managers, banks, insurance companies, and financial platforms to develop and execute their AI strategies.Currently, Charles is focused on applying Generative AI to financial services and advising many top financial institutions in building their own copilots and reimagining their businesses.Charles is a data scientist and machine learning engineer by profession and an expert in MLOps. Before joining Microsoft, Charles practiced data science, machine learning, and cloud engineering in the asset management industry. He has been a featured keynote speaker at several prestigious events and forums and is a highly sought after public speaker in the domain of AI and Innovation.